These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 15606790)

  • 21. Specific immunotherapy of cancer in elderly patients.
    Matzku S; Zöller M
    Drugs Aging; 2001; 18(9):639-64. PubMed ID: 11599633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.
    Chang MC; Chen YL; Lin HW; Chiang YC; Chang CF; Hsieh SF; Chen CA; Sun WZ; Cheng WF
    Mol Ther; 2018 Feb; 26(2):404-419. PubMed ID: 29248428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
    Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
    Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dendritic cells and their applications in cancer immunotherapy--achievements and future prospects].
    Rossowska J; Pajtasz-Piasecka E
    Postepy Hig Med Dosw; 2003; 57(5):501-18. PubMed ID: 14737967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies.
    Marr LA; Gilham DE; Campbell JD; Fraser AR
    Clin Exp Immunol; 2012 Feb; 167(2):216-25. PubMed ID: 22235997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer immunotherapy via dendritic cells.
    Palucka K; Banchereau J
    Nat Rev Cancer; 2012 Mar; 12(4):265-77. PubMed ID: 22437871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting neoantigens to augment antitumour immunity.
    Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM
    Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presentation of tumour antigens by dendritic cells and challenges faced.
    Robson NC; Hoves S; Maraskovsky E; Schnurr M
    Curr Opin Immunol; 2010 Feb; 22(1):137-44. PubMed ID: 20116984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetically modified tumour vaccines--where we are today.
    Nawrocki S; Mackiewicz A
    Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune modulation by dendritic-cell-based cancer vaccines.
    Kumar C; Kohli S; Bapsy PP; Vaid AK; Jain M; Attili VS; Sharan B
    J Biosci; 2017 Mar; 42(1):161-173. PubMed ID: 28229976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cells and cancer immunotherapy.
    Radford KJ; Tullett KM; Lahoud MH
    Curr Opin Immunol; 2014 Apr; 27():26-32. PubMed ID: 24513968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma.
    Behboudi S; Boswell S; Williams R
    Liver Int; 2010 Apr; 30(4):521-6. PubMed ID: 20040052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antigen trapping by dendritic cells for antitumor therapy.
    Pal C
    Methods Mol Biol; 2014; 1139():33-40. PubMed ID: 24619668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
    H Yi D; Appel S
    Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cells in cancer immunotherapy - a short review.
    Wojas K; Tabarkiewicz J; Roliński J
    Folia Morphol (Warsz); 2003 Nov; 62(4):317-8. PubMed ID: 14655109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour immunotherapy: the adjuvant treatment of the 21st century?
    Bremers AJ; Kuppen PJ; Parmiani G
    Eur J Surg Oncol; 2000 Jun; 26(4):418-24. PubMed ID: 10873365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
    Aguilar LK; Guzik BW; Aguilar-Cordova E
    J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigenic targets for renal cell carcinoma immunotherapy.
    Vieweg J; Jackson A
    Expert Opin Biol Ther; 2004 Nov; 4(11):1791-801. PubMed ID: 15500407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies of antigen-specific T-cell-based immunotherapy for cancer.
    Liu SH; Zhang M; Zhang WG
    Cancer Biother Radiopharm; 2005 Oct; 20(5):491-501. PubMed ID: 16248765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.